Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial

被引：8

作者：

Hu, Xiang ^{[1
]}

Chen, Lin ^{[2
]}

Du, Yian ^{[3
]}

Fan, Biao ^{[4
]}

Bu, Zhaode ^{[4
]}

Wang, Xin ^{[5
]}

Ye, Yingjiang ^{[6
]}

Zhang, Zhongtao ^{[7
]}

Xiao, Gang ^{[8
]}

Li, Fei ^{[9
]}

He, Qingsi ^{[10
]}

Li, Guoli ^{[11
]}

Shen, Xian ^{[12
]}

Xiong, Bin ^{[13
]}

Zhu, Liming ^{[14
]}

Liu, Jiwei ^{[15
]}

Liu, Lian ^{[16
]}

Wu, Tao ^{[5
]}

Zhou, Jing ^{[6
]}

Zhang, Jun ^{[7
]}

Zhao, Gang ^{[8
]}

Wang, Xulin ^{[11
]}

Liang, Pin ^{[1
]}

Wang, Xinxin ^{[2
]}

Zhang, Yan ^{[9
]}

Wu, Xiaojiang ^{[4
]}

Zhang, Ji ^{[4
]}

Ji, Xin ^{[4
]}

Zong, Xianglong ^{[4
]}

Fu, Tao ^{[4
]}

Jia, Ziyu ^{[4
]}

Ji, Jiafu ^{[4
]}

机构：

[1] Dalian Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Dalian 116011, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China

[3] Zhejiang Canc Hosp, Dept Abdominal Surg, Hangzhou 310022, Zhejiang, Peoples R China

[4] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Ctr Gastrointestinal Surg, Beijing 100142, Peoples R China

[5] Peking Univ, Hosp 1, Dept Gen Surg, Beijing 100034, Peoples R China

[6] Peking Univ, Peoples Hosp, Dept Gastrointestinal Surg, Beijing 100044, Peoples R China

[7] Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China

[8] Beijing Hosp, Dept Gen Surg, Beijing 100730, Peoples R China

[9] Capital Med Univ, Xuanwu Hosp, Dept Gen Surg, Beijing 100053, Peoples R China

[10] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Peoples R China

[11] Nanjing Gen Hosp, Dept Gen Surg, Nanjing 210002, Jiangsu, Peoples R China

[12] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Wenzhou 325000, Peoples R China

[13] Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China

[14] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China

[15] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian 116011, Peoples R China

[16] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan 250012, Peoples R China

来源：

CHINESE JOURNAL OF CANCER RESEARCH | 2017年 / 29卷 / 02期

基金：

美国国家科学基金会;

关键词：

Locally advanced gastric cancer; S-1 plus oxaliplatin; randomized phase III trial; ADJUVANT CHEMOTHERAPY; SURGERY; TEGAFUR;

D O I：

10.21147/j.issn.1000-9604.2017.02.07

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The ACTS-GC study had shown postoperative adjuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision. Methods: We have commenced a randomized phase III trial in December 2016 to evaluate S-1 plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer. A total of 564 patients will be accrued from 13 Chinese institutions in two years. The primary endpoint is 3-year relapse-free survival. The secondary endpoints are 5-year overall survival, proportion of patients who complete the postoperative chemotherapy and incidence of adverse events. Ethic and dissemination: The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient's follow-up will be ended until December, 2023.

引用

页码：144 / 148

页数：5

共 50 条

[31] A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)
Nishikawa, K.
Yoshino, S.
Morita, S.
Takahashi, T.
Sakata, K.
Nagao, J.
Nemoto, H.
Murakami, N.
Matsuda, T.
Hasegawa, H.
Shimizu, R.
Yoshikawa, T.
Osanai, H.
Imano, M.
Naitoh, H.
Yabe, M.
Tanaka, A.
Sakamoto, J.
Saji, S.
Oka, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S442 - S442
[32] Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study
Ryu, Min-Hee
Park, Young Lee
Chung, Ik-Joo
Lee, Keun-Wook
Oh, Ho-Suk
Lee, Kyung Hee
Han, Hye Sook
Seo, Bong -Gun
Jo, Jae-Cheol
Lee, Hyo Rak
Park, Sook Ryun
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002)
Chin, K.
Iishi, H.
Imamura, H.
Kobayashi, O.
Imamoto, H.
Esaki, T.
Kato, M.
Tanaka, Y.
Furukawa, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[34] Adjuvant chemotherapy for chemotherapy-naive advanced gastric cancer patients with oxaliplatin plus tegafur versus oxaliplatin plus S-1
Shu, Zhenbo
Ding, Dayong
Li, Yongchao
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (06): : 9322 - 9329
[35] Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)
Kang, Y-K.
Yook, J. H.
Park, Y-K.
Kim, Y-W.
Kim, J.
Ryu, M-H.
Rha, S. Y.
Chung, I-J.
Kim, I-H.
Oh, S. C.
Yoo, C-H.
Choi, J-H.
Zang, D. Y.
Kim, G.
Lee, Y.
Noh, S-H.
ANNALS OF ONCOLOGY, 2019, 30
[36] Protocol digest of a phase III trial to evaluate the efficacy of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA Trial)
Mizusawa, Junki
Tokunaga, Masanori
Machida, Nozomu
Yabusaki, Hiroshi
Kawabata, Ryohei
Imamura, Hiroshi
Kinoshita, Takahiro
Nomura, Takashi
Nunobe, Souya
Tsuji, Kunihiro
Katayama, Hiroshi
Fukuda, Haruhiko
Boku, Narikazu
Yoshikawa, Takaki
Terashima, Masanori
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (02) : 168 - 173
[37] Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study
Wang, Mei
Wu, Meihong
Wang, Wei
Wang, Qingshui
Wang, Yajie
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (1-2) : 24 - 28
[38] A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
Yang Lin
Song Yan
Zhou Ai-ping
Qin Qiong
Chi Yihebali
Huang Jing
Wang Jin-wan
CHINESE MEDICAL JOURNAL, 2013, 126 (18) : 3470 - 3474
[39] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP.
Kawase, Tomono
Imamura, Hiroshi
Gotoh, Masahiro
Kimura, Yutaka
Ueda, Shugo
Matsuyama, Jin
Nishikawa, Kazuhiro
Sugimoto, Naotoshi
Fujita, Junya
Tamura, Takao
Fukushima, Norimasa
Kawabata, Ryohei
Kurokawa, Yukinori
Shimokawa, Toshio
Sakai, Daisuke
Tsujinaka, Toshimasa
Furukawa, Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
Hyung, Jaewon
Cho, Hyungwoo
Kim, Hyung-Don
Park, Young Soo
Moon, Meesun
Ryu, Min-Hee
Kang, Yoon-Koo
GASTRIC CANCER, 2023, 27 (1) : 110 - 117

← 1 2 3 4 5 →